ACE-031 (Ramatercept)
Recombinant Fc-fusion decoy receptor (ActRIIB-Fc)
ACE-031 (ramatercept) is a fusion protein linking the activin receptor type IIB extracellular domain to an antibody Fc region, designed to trap myostatin and related ligands and thereby increase muscle mass. It reached early human trials, including in boys with Duchenne muscular dystrophy, but development was halted over vascular safety signals. It is investigational and not approved.
Mechanism under study
Its soluble ActRIIB extracellular domain fused to an Fc region acts as a ligand trap, sequestering myostatin, activin, and related GDF ligands to remove their negative regulation of muscle growth.
Research-reported dosing
Investigational; development was halted. Phase 1 and 2 trials, including in Duchenne muscular dystrophy, reported roughly 1-3 mg/kg subcutaneously every 2-4 weeks before discontinuation in 2013 over bleeding and vascular safety signals. Reported, not recommended.
An Fc-fusion biologic that in trials was handled as a sterile clinical solution rather than a consumer powder. If supplied as a research lyophilate, for example 1 mg, reconstituting with 2 mL bacteriostatic water would yield 500 mcg/mL, with 1 unit on a U-100 syringe (0.01 mL) about 5 mcg.
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
ACE-031 (Ramatercept) FAQ
What is ACE-031 (Ramatercept)?
ACE-031 (ramatercept) is a fusion protein linking the activin receptor type IIB extracellular domain to an antibody Fc region, designed to trap myostatin and related ligands and thereby increase muscle mass. It reached early human trials, including in boys with Duchenne muscular dystrophy, but development was halted over vascular safety signals. It is investigational and not approved.
What is the half-life of ACE-031 (Ramatercept)?
Long, as expected for an Fc-fusion protein, on the order of about two weeks, with trials dosing every 2-4 weeks.
What is the research-reported dosing for ACE-031 (Ramatercept)?
Investigational; development was halted. Phase 1 and 2 trials, including in Duchenne muscular dystrophy, reported roughly 1-3 mg/kg subcutaneously every 2-4 weeks before discontinuation in 2013 over bleeding and vascular safety signals. Reported, not recommended.
How is ACE-031 (Ramatercept) reconstituted?
An Fc-fusion biologic that in trials was handled as a sterile clinical solution rather than a consumer powder. If supplied as a research lyophilate, for example 1 mg, reconstituting with 2 mL bacteriostatic water would yield 500 mcg/mL, with 1 unit on a U-100 syringe (0.01 mL) about 5 mcg.
Is ACE-031 (Ramatercept) FDA-approved?
No — ACE-031 (Ramatercept) is investigational and not FDA-approved. It is sold for laboratory research use only.
References
Related peptides
Follistatin-344
Recombinant follistatin isoform (glycoprotein)
A recombinant isoform of follistatin, a natural inhibitor of myostatin, studied for its potential to increase muscle mass. Most human work uses gene therapy rather than the injected protein.
Somatropin (Recombinant HGH)
Recombinant peptide hormone (191-amino-acid growth hormone)
Somatropin is recombinant human growth hormone, the 191-amino-acid hormone itself rather than a secretagogue. It is FDA-approved across several growth-hormone-deficiency and growth-failure indications and is the hormone that peptides such as sermorelin, CJC-1295, and the GHRPs prompt the pituitary to release. Because it is the native hormone, its effects and risks are comparatively well characterized.
MGF (Mechano Growth Factor)
IGF-1 splice-variant peptide (IGF-1Ec)
MGF (Mechano Growth Factor) is a splice variant of IGF-1 known as IGF-1Ec, expressed transiently by muscle after mechanical loading or damage. The non-pegylated form described here is very short-acting and is distinct from the stabilized PEG-MGF variant. Evidence is preclinical and it is not an approved therapeutic.